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Abstract: Kenya is a country with a high tuberculosis (TB) burden. However, knowledge on the
genetic diversity of Mycobacterium tuberculosis complex (MTBC) strains and their transmission dynamics is sparsely available. Hence, we used whole-genome sequencing (WGS) to depict the genetic
diversity, molecular markers of drug resistance, and possible transmission clusters among MTBC
strains in urban and slum settings of Nairobi. We analyzed 385 clinical MTBC isolates collected
between 2010 and 2015 in combination with patients’ demographics. We showed that the MTBC
population mainly comprises strains of four lineages (L1–L4). The two dominating lineages were L4
with 55.8% (n = 215) and L3 with 25.7% (n = 99) of all strains, respectively. Genome-based cluster
analysis showed that 30.4% (117/385) of the strains were clustered using a ≤5 single-nucleotide polymorphism (SNP) threshold as a surrogate marker for direct patient-to-patient MTBC transmission.
Moreover, 5.2% (20/385) of the strains were multidrug-resistant (MDR), and 50.0% (n = 10) were
part of a genome-based cluster (i.e., direct MDR MTBC transmission). Notably, 30.0% (6/20) of the
MDR strains were resistant to all first-line drugs and are part of one molecular cluster. Moreover,
TB patients in urban living setting had 3.8 times the odds of being infected with a drug-resistant
strain as compared to patients from slums (p-value = 0.002). Our results show that L4 strains are the
main causative agent of TB in Nairobi and MDR strain transmission is an emerging concern in urban
settings. This emphasizes the need for more focused infection control measures and contact tracing
of patients with MDR TB to break the transmission chains.
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1. Introduction
Tuberculosis (TB) is still a major cause of morbidity and mortality worldwide, especially in Sub-Saharan Africa [1–3]. In 2020, TB was responsible for 9.9 million new cases,
of which 25% were in the World Health organization (WHO) African region [1]. Kenya is
among the highest TB burden countries with an incidence of 259/100,000 population, which
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is twice as much as the global average [1–3]. The total number of new and relapse TB case
notifications was 71,646 [1]. The HIV/AIDS epidemic and the emergence of drug-resistant
Mycobacterium tuberculosis complex (MTBC) strains complicated the effective control of TB
in the country [4,5]. Additionally, the emergence of SARS-CoV-2 is expected to have a longlasting impact leading to an increase in the burden of TB in Kenya due to the disruption of
TB health care services in 2020 [6,7]. Moreover, the lack of resources to carry out proper
and definitive diagnosis of TB fuels the country’s TB epidemic as TB diagnosis is solely
performed using smear microscopy in Kenya. This technique has a variable sensitivity
and does not allow for resistance prediction or differentiation between infections due to
MTBC and non-tuberculous mycobacteria (NTM) [8,9]. TB cases are therefore treated using
empirical treatment which may foster the development and transmission of resistant MTBC
strains by long periods of infectivity [10].
In Kenya, knowledge on genetic drug resistance markers of MTBC strains is inadequate,
especially in potential transmission hotspots, such as the capital Nairobi. Molecular epidemiological studies have suggested that transmission is a major driver of drug susceptible and
drug resistant TB epidemics, not only in Eastern Europe but also in Africa [10–13]. Indeed,
MTBC transmission is one of the major constraints that hinder TB control, particularly in
poor settings (e.g., slums) where the risk of transmission is high due to overcrowding [1,13].
Evidence has disclosed high TB prevalence in slums in Kenya [14] and other African countries, such as South Africa [15,16]. Furthermore, patients in slums may have limited access
to TB treatment centers.
Here, we collated MTBC strains from two patient cohorts in Nairobi to analyze differences in the genetic diversity, transmission dynamics, and molecular drug resistance
profiles of MTBC strains circulating in slum and urban settings.
2. Materials and Methods
2.1. Study Design and Setting
We enrolled self-presented presumptive TB patients in this cross-sectional study who
had respiratory symptoms and were smear-positive from 13 randomly selected health
centers located in Nairobi and its surroundings (Figure S1, Table S1). The first cohort
(n = 204) was enrolled between May 2010 and May 2013, and the second cohort (n = 275)
was enrolled from September 2014 to May 2015. Three of the health care centers selected are
TB referral centers (Table S1), of which one center is located in slums (i.e., highly populated
or informal settlements with weak building quality, inadequate housing or very small living
spaces, and squalid conditions which are often associated with poverty) and serves up to
200 patients per week. Each patient was required to give a spot (i.e., collected at the time
of first visit of the patient to clinic/laboratory) and an early morning sputum sample for
analysis. Both spot and early morning samples were pooled and used for microbiological
analysis. Demographic data were gathered using a structured questionnaire, and each
recruited patient was assigned a unique personal identifier that was used throughout the
study period.
2.2. Laboratory Procedures
2.2.1. Sputum Decontamination, Mycobacterial Culture, and DNA Extraction
All specimens were processed and decontaminated following the standard N-acetyl-Lcysteine—sodium hydroxide (NALC-NaOH) method for digestion, decontamination, and
concentration [17]. The sediment was resuspended in about 1 to 2 mL phosphate buffer
(pH 6.8) and mixed thoroughly. A smear was prepared for acid-fast staining [9,18].
Mycobacterial cultures were performed by adding 0.25 mL of the suspended decontaminated samples into the BACTEC MGIT 960 (Becton Dickinson, Franklin Lakes, NJ,
USA) and onto solid Löwenstein–Jensen (LJ) culture media [19].
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DNA extraction from mycobacterial colonies was carried out using the cetyl trimethylammonium bromide (CTAB) method as described by Somerville et al. [20]. The DNA
was reconstituted with molecular grade water and stored at −20 ◦ C until it was sent to
the Molecular and Experimental Mycobacteriology Laboratory, Research Centre Borstel in
Germany, where molecular characterization of the MTBC strains was conducted.
2.2.2. Whole-Genome Sequencing
DNA libraries for whole-genome sequencing (WGS) were prepared with the Nextera
(XT) kit from Illumina (San Diego, USA) according to the manufacturer’s instructions [21].
Pooled DNA libraries were then loaded into NextSeq Reagent cartridges for sequencing on
a NextSeq system (Illumina, San Diego, CA, USA). Resulting sequencing reads were submitted to the European Nucleotide Archive under the project accession number PRJEB50767
and subsequently mapped to the H37Rv reference genome (GenBank ID: NC_000962.3)
by Burrows–Wheeler alignment (BWA) tool aiming for a minimum of 50-fold average
genome-wide coverage [22,23]. We considered single nucleotide polymorphisms (SNPs)
with at least 4 reads in both forward and reverse orientation, 4 reads calling the allele
with at least a Phred score of 30, and 75% allele frequency for a concatenated sequence
alignment. SNP positions that had reliable base call (as described above) in at least 95% of
the strains were concatenated to a sequence alignment. SNPs from repetitive regions were
excluded, including those which occurred within a window of 12 base pairs in neighboring
strains [23].
A web tool was used for detecting isolates that harbored more than one phylogenetic
lineage (i.e., mixed infections or laboratory contaminations) [24]. These samples/isolates
were not considered in subsequent analysis.
2.3. Data Analysis
2.3.1. Phylogenetic Reconstruction and WGS-Based Cluster Inference
On the basis of concatenated sequence data, the most suitable substitution model for
the dataset was implemented using the maximum likelihood ratio test (Jmodel test) [25]. A
maximum likelihood tree was calculated based on the concatenated sequence alignment
using FastTree [26] with a general time-reversible (GTR) substitution model (best according
to Jmodel test), 1000 resamples, and γ 20 likelihood optimization to account for the rate of
heterogeneity among sites. The phylogenetic tree was inspected and rooted with FigTree
software (Institute of Evolutionary Biology, University of Edinburgh, Edinburgh, Scotland).
Graphical presentation was performed with Evolview [27]. The concatenated sequence
data were also used to calculate maximum parsimony trees using BioNumerics software
version 7.6 (Applied Maths, BioMérieux, Sint-Martens-Latem, Belgium). Genome clusters
were defined by grouping all sequenced isolates within a maximum distance of ≤12 and
≤5 SNPs between one strain and the neighboring strain [28,29].
2.3.2. Molecular Drug Resistance Prediction
Genes associated with drug resistance mechanisms were individually investigated
and not considered for phylogenetic approaches [24].
The SNP dataset was examined for known resistance-conferring mutations against
first-line and second-line antibiotics [24]. In brief, for rifampicin (RIF) resistance, mutations
that confer resistance on the rpoB gene were analyzed. Other RNA-polymerase genes,
i.e., rpoA and rpoC, were analyzed with regard to putative compensatory mutations. We
also investigated katG, inhA, ndh, and fabG1 genes for mutations that confer resistance to
isoniazid (INH). We screened pncA and rpsA genes for mutations conferring resistance
to pyrazinamide (PZA), and embB, embC, and embA genes for mutations associated with
ethambutol (EMB) resistance. In the case of streptomycin (STR) resistance, the rpsL, rrs, and
gidB genes were investigated for mutations conferring resistance. For isolates that were
MDR (i.e., resistance towards INH and RIF), genes conferring resistance against secondline drugs were examined. The gyrA and gyrB genes were investigated for resistance
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against fluoroquinolones (FQs), while the rrs gene was studied for resistance against
aminoglycosides. In addition, tlyA and thyA genes were analyzed for capreomycin (CAP)
and para-aminosalicylic acid (PAS) resistance, respectively. For ethionamide (Eto) resistance,
ethA and fabG1 genes were studied [24].
2.3.3. Statistics
Demographic data were entered, cleaned, and analyzed using the SPSS statistical
software package, version 20 (SPSS Inc., Chicago, IL, USA). Chi-square test and Fisher exact
test were used to compare categorical variables. All variables were tested using logistic
regression analysis. A p-value ≤ 0.05 was considered significant.
2.4. Ethical Considerations
This study was approved by the Scientific and Ethical Review Unit of Kenya Medical
Research Institute (SSC Protocol No. 2830). All patients recruited into the study were
required to sign a written informed consent for collection and analysis of samples and
demographic and clinical data. If the patient was illiterate or less than 18 years old,
a caretaker was requested for consent. All the information collected from cases was
kept confidential. All patient identifiers were removed prior to data analysis. During
the study, any diagnosed TB cases (i.e., smear-positive) were registered at the health
centers and treated according to the National Tuberculosis and Leprosy Programme (NTLP)
guidelines [30].
The NTLP guidelines state that all patients who have not been on TB therapy previously should have a two-month initial phase of treatment consisting of INH, RIF, PZA, and
EMB followed by a continuation phase of EMB and INH for six months or INH and RIF for
four months [30]. For retreatment TB patients, the intensive phase is three months of daily
injections of STR and swallowing of INH, RIF, PZA, and EMB, followed by five months of
continuation phase with INH, RIF, and EMB [30].
3. Results
3.1. Study Population
A total of 479 sputum samples were collected from smear-positive patients in health
centers in Nairobi and its surroundings (Figure S1). Based on hospital records, the recruited
patients comprised 10–20% of all patients who received a diagnosis of TB during the
study period.
After excluding individuals with missing data, we found that the overall mean age
of the investigated patients was 31.7 ± 8.3 years. Moreover, we observed that most of the
enrolled individuals (64.4%, 246/382) were males and were newly diagnosed TB cases
(85.3%, 326/382). Most of the study cases were from health centers located in non-slum
areas (i.e., urban or developed areas with well-constructed houses, commercial buildings,
roads, and bridges) (55.8%, 215/385), while 44.2% (170/385) were from health centers
located in slums (informal settlements) (Table S1).
Out of all collected sputum specimens, 48/479 (10.0%) were either culture-negative
or contaminated (Figure 1). Furthermore, 31 isolates were subsequently excluded from
the analysis due to quality issues or the identification of more than one strain (n = 15)
in the DNA isolate. The final analysis comprised 385/479 (80.4%) WGS datasets, each
representing one isolate per patient (Figure 1).
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vealed significant
differences between the proportions of drug-susceptible and drug-restrains (X2 = 25.3, p-value ≤ 0.001), the proportions of clustered and not clustered strains
sistant strains (X2 = 25.3, p-value
≤0.001), the proportions of clustered and not clustered
based on ≤5 SNP threshold (X2 = 14.2, p-value ≤ 0.001), and the proportions of male and
strains based2on ≤5 SNP threshold (X2 = 14.2, p-value ≤ 0.001), and the proportions of male
female sex (X = 4.97, p-value = 0.026) after excluding individuals with missing information
and female sex (X2 = 4.97, p-value = 0.026) after excluding individuals with missing inforfrom the analysis (Table 1). Furthermore, the proportions of patients residing in urban
mation from the analysis (Table 1). Furthermore, the proportions of patients residing
in
and slum living conditions differed significantly between the two cohorts (X2 = 178.2,
urban and slum living conditions differed significantly between the two cohorts (X2 =
p-value ≤ 0.001). While in the 2010 cohort 91.7% (166/181) of the patients came from urban
178.2, p-value ≤ 0.001). While in the 2010 cohort 91.7% (166/181) of the patients came from
areas, only 24.0% (49/204) of the patients from the 2014–2015 cohort were living in an
urban areas, only 24.0% (49/204) of the patients from the 2014-2015 cohort were living in
urban setting (Table 1).
an urban setting (Table 1).
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Table 1. Comparison of the two patient cohorts investigated by using chi-square test in Nairobi,
Kenya (2010–2015).
Variable

No.

Cohort A

Cohort B

Lineage
L1 (EAI)
L2 (Beijing)
L3 (Delhi/CAS)
L4 (Euro-American)
M. bovis

14
56
99
215
1

9 (5.0%)
30 (16.6%)
52 (28.7%)
89 (49.2%)
1 (0.5%)

5 (2.5%)
26 (12.7%)
47 (23.0%)
126 (61.8%)
0 (0.00%)

DST
Susceptible
MDR
Non-MDR

348
20
17

151 (83.4%)
20 (11.1%)
10 (5.5%)

197 (96.6%)
0 (0.00%)
7 (3.4%)

d12
Clustered
Not clustered

218
167

111 (61.3%)
70 (38.7%)

107 (52.5%)
97 (47.5%)

d5
Clustered
Not clustered

117
268

72 (39.8%)
109 (60.2%)

45 (22.1%)
159 (77.9%)

TB history
New
Retreatment
NA *

326
56
3

152 (84.0%)
28 (15.5%)
1 (0.5%)

174 (85.3%)
28 (15.5%)
2 (1.0%)

Age group
≤30
>30
NA *

166
161
58

63 (34.8%)
62 (34.3%)
56 (30.9%)

103 (50.5%)
99 (48.5%)
2 (1.0%)

Sex
Male
Female
NA *

246
136
3

105 (58.0%)
75 (41.4%)
1 (0.6%)

X2

p-Value

7.70

0.103

25.3

<0.001 a

3.08

0.079

14.2

<0.001 a

0.11

0.747

0.11

0.917

4.97

0.026 a

178.2

<0.001 a

–

–

141 (69.1%)
61 (29.9%)
2 (1.0%)

Sampling area
Urban
Slum

215
170

166 (91.7%)
15 (8.3%)

49 (24.0%)
155 (76.0%)

Total

385

181 (47.0%)

204 (53.0%)

No. = number, A = cohort 2010, B = cohort 2014–2015, DST = drug susceptibility testing, MDR = simultaneous
resistance towards isoniazid and rifampicin, non-MDR = resistance towards drugs other than isoniazid and
rifampicin, d12 = genetic distance of ≤12 single-nucleotide polymorphisms (SNPs), d5 = genetic distance of
≤5 SNPs, NA = not available, * = variable (individuals with missing data) excluded from analysis, a = variable
with a chi-square p-value of ≤ 0.05.

3.2. MTBC Population Structure
We performed WGS successfully on 400 MTBC strains. We excluded 15 samples/datasets
from the final analysis because of the identification of more than one strain and built a
maximum likelihood phylogeny upon a concatenated sequence alignment comprising
18,167 SNPs to investigate the MTBC population structure using 385 strains (Figure 2).
Phylogenetic lineages (Ls) were inferred from canonical SNPs specific for certain MTBC
sublineages based on a recently introduced SNP barcode classification [31,32]. Strains of L4
(Euro-American super-lineage, n = 215/385, 55.8%) were predominant, followed by strains
of L3 (Delhi/CAS, n = 99/385, 25.7%), strains of L2 (Beijing, n= 56/385, 14.5%), and strains
of L1 (East African Indian, n = 14/385, 3.6%). There was one M. bovis strain identified
(Figure 2).
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(LAM) genotype (n = 70/215, 32.5%) comprised the MTBC sublineages 4.3.2, 4.3.4.1, 4.3.4.2,
and 4.3.4.2.1 and were most frequent, followed by S-type (4.4.1.1, n = 55/215, 25.5%), Turkish (TUR) (4.2.2, n = 27/215, 12.6 %), and Haarlem (4.1.2 and 4.1.2.1, n = 18/215, 8.4%) (Figure S2). Other sublineages identified include Kenya H37Rv-like (4.8, n = 13/215, 6%),
Uganda I (4.6.1.1, n = 7/215, 3.2%), Uganda II (4.6.1.2 n = 10/215, 4.6%), X-type (4.1.1.1,7nof=15
7/215, 3.2%), Cameroon (4.6.2 n = 6/215, 2.8%), Ghana (4.1 n = 1/215, 0.5%), and undefined
Euro-American (4.0, n = 1/215, 0.5%) (Figure S2).

Figure 2. MTBC population structure in urban and slum areas of Nairobi, Kenya. Maximum likeliFigure 2. MTBC population structure in urban and slum areas of Nairobi, Kenya. Maximum likelihood tree based on 18,167 concatenated single-nucleotide polymorphisms (SNPs) using a general
hood
tree based substitution
on 18,167 concatenated
single-nucleotide
polymorphisms
(SNPs)
using
general
time-reversible
model. Colored
bars code for (inner
to outer ring)
M. bovis
andaMTBC
time-reversible
substitution
model.
Colored
bars
code
for
(inner
to
outer
ring)
M.
bovis
and
MTBC
lineages (L1–4); genotypic DST results stratified to MDR, non-MDR, and fully susceptible; sampling
lineages
genotypic
DST
results stratified
MDR,distance
non-MDR,
fullyDST
susceptible;
sampling
location;(L1–4);
and clustered
and
non-clustered
strainsto(SNP
≤12 and ≤5).
= drug susceptibility testing,
MDR = multidrug-resistant
(simultaneous
resistance
and susceptirifamlocation;
and clustered
and non-clustered strains
(SNP distance
≤12towards
and ≤5).isoniazid
DST = drug
picin);
Pre-XDR=
pre-extensively
drug-resistant
(an
MDR
which
is
also
resistant
to
any
fluoroquinbility testing, MDR = multidrug-resistant (simultaneous resistance towards isoniazid and rifampicin);
olone), MTBC
= Mycobacterium
tuberculosis(an
complex.
Pre-XDR=
pre-extensively
drug-resistant
MDR which is also resistant to any fluoroquinolone),

MTBC = Mycobacterium tuberculosis complex.

3.3. Genome-Based Drug Resistance Prediction

Overall,of37
the 385 (9.6%) MTBC
isolates investigated
foundinto
to be
reStrains
L4out
(theofEuro-American
super-lineage)
were furtherwere
classified
several
sistant to atasleast
one of previously
the first-line
drugs,Strains
of which
20 (5.2%)
were MDR.
Monodrug
sublineages
described
[31,32].
of the
Latin American
Mediterranean
(LAM) genotype (n = 70/215, 32.5%) comprised the MTBC sublineages 4.3.2, 4.3.4.1, 4.3.4.2,
and 4.3.4.2.1 and were most frequent, followed by S-type (4.4.1.1, n = 55/215, 25.5%),
Turkish (TUR) (4.2.2, n = 27/215, 12.6 %), and Haarlem (4.1.2 and 4.1.2.1, n = 18/215, 8.4%)
(Figure S2). Other sublineages identified include Kenya H37Rv-like (4.8, n = 13/215, 6%),
Uganda I (4.6.1.1, n = 7/215, 3.2%), Uganda II (4.6.1.2 n = 10/215, 4.6%), X-type (4.1.1.1,
n = 7/215, 3.2%), Cameroon (4.6.2 n = 6/215, 2.8%), Ghana (4.1 n = 1/215, 0.5%), and
undefined Euro-American (4.0, n = 1/215, 0.5%) (Figure S2).

3.3. Genome-Based Drug Resistance Prediction
Overall, 37 out of the 385 (9.6%) MTBC isolates investigated were found to be resistant
to at least one of the first-line drugs, of which 20 (5.2%) were MDR. Monodrug resistance to
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INH, RIF, or PZA was observed in 15 (3.9%), 1 (0.3%), and 1 (0.3%) of the MTBC strains,
respectively (Table S1).
A detailed analysis of variants in resistance-associated genes revealed that 9.1%
(35/385) of the strains had mutations conferring resistance to INH, with the Ser315Thr in
the katG gene being the dominant observed mutation (60.0%, 21/35) (Table 2). The -15 c/t
mutation in the fabG-inhA promoter region was the second most dominant INH resistance
determinant (22.8%, 8/35). Variants in the rpoB gene that confer resistance to RIF were
found in 21 (5.5%) strains, with the Ser450Leu mutation being the most common (52.3%,
11/21) (Table 2). Moreover, mutations at codon 445 leading to His445Tyr, His445Arg, and
His445Asp amino acid substitutions were observed in seven (33.3%) strains.
Table 2. Detected mutations that mediate resistance to first-line anti-TB drugs in 37 resistant MTBC
strains in urban and slum areas of Nairobi, Kenya (2010–2015).
Drug

Gene
katG

INH

fabG1-inhA
inhA

Mutation

Codon Change

Total

Ser315Thr
Ser315Arg
−15 c/t
Leu203Leu
Ile194Thr

agc/aCc
agc/aGa
C→T
ctg/ctA
atc/aCc

21
2
8
2
2

Caa/cCa
Cac/Tac
Cac/cGc
Cac/Gac
Tcg/tTg
Ctg/cCg

2
5
1
1
11
1

RIF

rpoB

Gln432Pro
His 445Tyr
His 445Arg
His445Asp
Ser450Leu
Leu452Pro

STR

rpsL
gidB
rrs

Lys43Arg
Ala138Val
513 a/c

Aag/aGg
Gcg/gTg
A→C

9
1
3

embB

Met306Ile
Met306Val
Asp328Gly
Asp354Ala

Atg/atA
Atg/Gtg
Gat/gGt
Gac/Aac

7
2
1
1

PZA

pncA

Gln10Pro
His57Asp
Asp63Gly
Lsy96Thr
Thr135Pro
Gln141_

cag/cCg
cac/Gac
gac/gGc
aag/aCg
acc/Ccc
cag/tag

1
1
2
6
1
1

FQs

gyrA

Asp94Gly

gac/Cac

1

EMB

INH = isoniazid, RIF = rifampicin, STR, streptomycin, EMB = ethambutol, PZA = pyrazinamide, FQs = fluoroquinolones.

The most common mutation mediating STR resistances was the Lys43Arg (69.2%,
9/13) at the rpsL gene, followed by the 513 a/c (23.0%, 3/13) mutation in the rrs gene.
Eleven strains were resistant to EMB, with Met306Ile being the frequent mutation observed
in the embB gene (63.6%, 7/11) (Table 2). The pncA gene was analyzed for mutations
conferring resistance to PZA. The Lys96Thr mutation was found to be the most common
(50.0%, 6/12).
Only one strain was found with a fluoroquinolone resistance mediating mutation in
the gyrA gene (Asp94Gly, 1/385, 0.3%). This strain was hence defined as pre-extensively
drug-resistant (XDR) which is an MDR and resistant to any fluoroquinolone. There were
no resistance markers identified for other second-line anti-TB drugs.
When we compared the proportions of drug-resistant (i.e., any antibiotic resistance)
and wild-type (fully susceptible) strains between sex groups, age groups, and TB history,
we found no differences between male and female, ≤30 and >30 age groups, and new
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and retreatment TB cases with a p-value of ≥0.247 (Table 3). However, the proportion of
infection with a drug-resistant strain was observed to be significantly associated with urban
living conditions (OR = 3.8, 95% CI 1.62–8.83, p-value = 0.002) (Table 3). Notably, all MDR
strains detected in this study were found in urban areas.
Table 3. Comparison of the proportions of drug-susceptible and drug-resistant strains across the
sociodemographic variables and MTBC phylogenetic lineages by using logistic regression in Nairobi,
Kenya (2010–2015).

Variables

No.

No. of Wild
Type

No. of
Resistant
(%)

Gender
Male

246

226

20 (8.10)

Female

136

120

16 (11.8)

NA *

3

2

1 (33.3)

Age
≤30

166

148

18 (10.8)

>30

161

149

12 (5.70)

NA *

58

51

7 (12.1)

Study area
Slum

170

163

7 (4.1)

Urban

215

185

30 (14.0)

TB history
New

326

296

30 (9.2)

Retreatment

56

50

6 (10.7)

NA *

3

2

1 (33.3)

Lineage
L2 (Beijing)

56

52

4 (7.1)

L1 (EAI)

14

11

3 (21.4)

L3 (Delhi/CAS)

99

89

10 (10.1)

L4 (Euro-American)

215

196

19 (8.8)

1

0

1 (100)

Ref
3.5
(0.69–18.1)
1.5
(0.44–4.89)
1.3
(0.41–3.86)
–

385

348

37 (9.6)

–

M. bovis *
Total

OR
(95% CI)

p-Value

Ref
1.5
(0.75–3.01)
–

0.247

Ref
1.5
(0.70–3.24)
–

0.291

Ref
3.8
(1.62–8.83)
Ref
1.2
(0.47–2.99)
–

–

–

0.002

0.721
–

0.129
0.539
0.868
–
–

No. = number, OR = odds ratio, CI = confidence interval, NA = not available, L = lineage, * = variable (individuals
with missing data) excluded from the regression model.

Overall, 30% (6/20) of the MDR MTBC strains were identified with molecular resistant
markers to all first-line drugs (Table S1). Furthermore, L3 (7/20, 35.0%) and L4 (7/20,
35.0%) equally dominated among the MDR TB strains. Comparison of the proportions of
drug-resistant strains across the phylogenetic lineages (L1–L4) using logistic regression
revealed no statistical differences (Table 3).
3.4. Genome-Based Cluster Analysis
We performed a genome-based cluster analysis with thresholds of a maximum genetic
distance of ≤12 and ≤5 SNPs between any two MTBC strains to obtain an indication of
potential TB transmission events [28,29]. Overall, 56.6% (218/385, 95% CI 51.6–61.5) of the
MTBC strains were grouped into 61 genome clusters based on a ≤12 SNP basis. The cluster
size ranged between 2 and 28 strains/patients per cluster (Figure S3). If a stricter genetic
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distance of ≤5 SNPs was used for cluster analysis, 30.4% (117/385, 95% CI 26.0–35.2) of the
strains were grouped into 41 clusters ranging from 2 to 21 strains/patients (Figure S4).
Stratifying by phylogenetic MTBC lineage showed that L2 strains had the highest
genome clustering rate using both ≤12 and ≤5 SNP distance (66.1% and 35,7%), followed
by L4 (57.2% and 34,4%). L2 and L4 strains further had a higher odds ratio to be in a
molecular cluster (L2, OR 2.1, p-value= 0.051 and L4 OR 1.9, p-value = 0.019) using a
SNP threshold of ≤5 (Table 4). This indicates that L2 and L4 strains are more effectively
transmitted as compared to L3 strains. However, a statistical difference was only observed
for the strict threshold of ≤5 SNP genetic distance (Table 4).
Table 4. Comparison of the proportions of clustered and not clustered strains across the detected
MTBC phylogenetic lineages by using logistic regression in Nairobi, Kenya (2010–2015).

Variable

No.

d12

d5

NC

C (%)

OR (95% CI)

p-Value

NC

C (%)

OR (95% CI)

p-Value

99
56

45
19

Ref
1.6 (0.82–3.20)

0.163

78
36

21 (21.2%)
20 (35.7%)

Ref
2.1 (1.00–4.28

0.051

215

92

54 (54.5%)
37 (66.1%)
123
(57.2%)

1.1 (0.69–1.80)

0.658

141

74 (34.4%)

1.9 (1.12–3.41)

0.019

L1 (EAI) *
M. bovis *

14
1

10
0

4 (28.6%)
0 (0.00%)

–
–

–
–

12
0

2 (14.3%)
0 (0.00%)

–
–

–
–

Total

385

166

218 (56.6)

–

–

267

117 (30.5)

–

–

Lineage
L3 (Delhi/CAS)
L2 (Beijing)
L4 (EuroAmerican)

No. = number, d12 = genetic distance of ≤12 single-nucleotide polymorphisms (SNPs), d5 = genetic distance ≤ 5 SNPs,
NC = number of not clustered, C = number of clustered, OR = odds ratio, CI = confidence interval, NA = not
available, * = variable excluded from the regression model.

Among the strains of the L4 MTBC sublineages, strains of the L4.4.1.1 (S-type) sublineage formed the largest genome cluster comprising 28 strains/patients. Overall, L4.4.1.1
(S-type) (OR 2.19, p = 0.001), L4.1.1.1 (X-type) (OR 2.7, p = 0.028), and L4.8 (Kenya H37Rvlike) (OR 2.12, p = 0.017) were significantly associated with molecular clusters.
3.5. Transmission of MDR MTBC Strains
Based on ≤12 and ≤5 SNP genetic distances, 60% (12/20, three clusters) and 50%
(10/20, three clusters) of MDR strains were clustered, respectively (Figure S5). Within
the genomic clusters, MDR strains showed identical resistance-conferring mutations in
the katG gene. In the rpoB gene, most strains (11/20, 55.0%) carried the rpoB mutation
Ser450Leu as well as katG Ser315Thr (18/20, 90%). The largest MDR cluster (with both
thresholds, ≤12 and ≤5 SNPs) comprised six L4.4.1.1 (S-type) strains that all shared the
following resistance-conferring mutations: katG Ser315Thr, rpoB Ser450Leu, pncA Lys96Thr,
rpsL Lsy43Arg, and embB Met306Ile. One of the strains of this cluster already evolved to
pre-XDR. All patients within this MDR cluster were from urban living areas in Nairobi.
4. Discussion
In this study, we elucidated the MTBC population structure and transmission events
in Nairobi, Kenya, by using WGS. We showed that pulmonary TB is dominantly caused
by strains of L4 and L3 and noted a substantial cluster rate which points towards ongoing
transmission of MTBC strains. Moreover, all patients infected with MDR strains were from
urban areas of Nairobi. We further found a cluster that consists of strains that are resistant
to all first-line anti-TB drugs, with one of them already evolved to pre-XDR. These findings
emphasize the need for more focused infection control measures and contact tracing of
patients with MDR TB to break the transmission chains.
We revealed that the MTBC population comprises strains of four lineages in Nairobi,
namely L1–L4 and one M. bovis strain. Strains of L4 and L3 are the main causative agents
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of TB comprising 55.8% and 25.7% of the investigated strains, respectively. These findings mirror reports from neighboring countries, such as Ethiopia [33], Tanzania [34], and
Uganda [35] but are in contrast to the findings from Shuaib et al. [12] and Ejo et al. [36] in
Eastern Sudan and Northwest Ethiopia where L3 strains were the main etiological agent
of TB.
We found that strains of the LAM (L4.3.1, L4.3.3, and L4.3.4) sublineages are the
most prevalent in Nairobi in comparison with strains of other L4 sublineages. Stucki
et al. [37] have identified strains of certain sublineages of L4, such as LAM (L4.3), Haarlem
(L4.1.2), and PGG3 (L4.10), as generalists as these strains can cause TB in all host genetic
backgrounds globally. Therefore, the high prevalence of the strains of the generalist LAM
sublineage might explain the dominance of L4 strains in Nairobi in Kenya. Another possible
explanation for the success of L4 might be related to the observation that some L4 strains
are capable of evading the host immune response and rapidly progressing to TB disease
and thus are more often transmitted [15,36].
As mentioned before, L3 strains were the second most prevalent causative agent
of TB in Nairobi. It’s been previously suggested that L3 strains have an evolutionary
origin in South Asia. However, L3 strains have frequently been isolated from TB patients
in East and North Africa [12,34,36,38], and one could speculate if these strains have coevolved with and adapted to their East African hosts and consequently developed specific
biological/phenotypic traits in this particular host population [12]. The high prevalence of
L3 strains in Kenya could also be related to recent and/or past movements of people from
the Indian subcontinent (i.e., migration, tourism, and trade).
In this study, we found that L2 strains comprised 14.5% of the investigated strains,
which is higher than former reports where the prevalence of L2 strains was 8.4% in 2004 [39].
This upward trend indicates that strains of this lineage are also successfully transmitted
in the population. Moreover, the reported proportion of L2 strains in the present study
is higher than that in other countries of the region, including Sudan (0.6%) [12], Tanzania
(4.1%) [34], Uganda (1.2%) [38], and Ethiopia (0.5%) [40]. It is known that L2 strains have
their origin in East Asia, where they are responsible for multiple TB epidemics [10,41]. The
expansion of L2 strains on the African continent has been suggested to be associated with
increased transmission, high virulence, and a rapid progression to disease, rather than with
drug resistance [10,41]. In addition, labor migration has been discussed as a possible factor
explaining the increasing prevalence of L2 strains, mainly in East African countries [41].
We found evidence of direct patient-to-patient MTBC transmission as one-third (i.e.,
30.4%) of the isolates/patients were associated with genomic clusters using a ≤5 SNP
threshold in this study. Surprisingly, the transmission of TB is significantly higher in urban
areas than in slum areas of Nairobi using both ≤12 and ≤5 SNP distances (34.9% in urban
areas vs. 24.7% in slum areas, Exp(B) = 1.6, p-value = 0.032). This indicates that a higher
risk of being infected due to transmission is related to a certain hotspot. Comparing the
cluster rate across all phylogenetic lineages showed that L2 and L4 strains had an increased
odds ratio of being in a molecular cluster (d5: L2, OR 2.1, p-value = 0.051 and L4 OR 1.9,
p-value = 0.019). Additionally, among the strains of L4 MTBC sublineages, strains of the
S-type, X-type, and Kenya H37Rv-like are likely more successful, i.e., have a higher odds to
be in a molecular cluster. The observed cluster rate in Nairobi is comparable to the cluster
rates reported in other high TB burden countries, such as Sudan [12], South Africa [16], and
Ethiopia [42].
Early detection of resistance to anti-TB drugs is important for successful treatment
and control of MDR TB [43]. In this study, 9.6% of the strains were found to be resistant to
at least one first-line anti-TB drug, with 5.2% being MDR strains. This proportion of MDR
strains is higher than those previously reported in Kenya [44,45] and in other countries,
e.g., Uganda (1.7%) [46]. Nevertheless, in Sudan (9.0%) [12] and Tanzania (6.3%) [47],
higher proportions of MDR strains have been reported. The variations in resistance rates
observed in our study and the previous studies in Kenya could be due to the study design
and sample size obtained [44,45]. Information on susceptibility patterns of strains against
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anti-TB drugs is essential for the control and surveillance of TB. Therefore, early diagnosis
and treatment, improving treatment outcomes, and expanding diagnostic capacity for
mycobacterial culture and drug susceptibility testing are crucial to limit the spread of
drug resistant MTBC strains, especially MDR. In the case of the MDR and RR TB cases,
rapid detection of resistance, e.g., by GeneXpert, followed by extended phenotypic drug
susceptibility testing is essential for patient isolation and establishment of second-line
anti-TB therapy. Otherwise, prolonged periods of ineffective treatment will likely allow
continuous transmission of MDR cases with disastrous consequences for TB control in
the future.
Furthermore, we found a high cluster rate among MDR strains (60% based on ≤12 SNP
threshold and 50% based on ≤5 SNP threshold) in combination with an increased risk of
infections with drug-resistant strains in urban living areas in Nairobi. This is in line with a
recent Kenya TB prevalence survey that indicated that the majority of TB cases are found
in urban areas [14]. Therefore, successful control of TB in these settings should focus on
addressing the influence of associated social and economic factors as well as strengthen
TB control measures including contact tracing, early TB case detection, and adherence
to treatment.
One limitation of our study is the lack of comprehensive epidemiological and clinical
data, such as HIV status, diabetes, and other comorbidities, as well as treatment outcome.
This limited a detailed analysis of epidemiological and clinical factors associated with
recent transmission of MTBC strains (i.e., by using number of clustered strains as surrogate).
Another limitation is the sampling bias of the two cohorts. Higher proportions of MDR
and clustered strains were collected mainly from TB patients living in urban areas in the
2010 study cohort. This could have biased the association between any drug resistance and
urban settings in the combined analysis.
5. Conclusions
Our study demonstrates that TB is predominantly caused by L4 strains in the urban
and slum settings of Nairobi, Kenya. WGS analysis provides a better understanding of
transmission dynamics of MTBC strains and their molecular drug resistance determinants.
We found a cluster of strains that are resistant to all first-line anti-TB drugs. One of
the strains of this molecular cluster has already evolved to a pre-XDR genotype via the
acquisition of FQ resistance. Importantly, we observed that all MDR strains are associated
with urban living environments and half of them are linked to direct patient-to-patient
transmission, highlighting the urgent need to increase efforts to identify MDR TB cases and
trace patient contacts to contain the spread of the disease in Nairobi. Adoption of the use
of WGS may further allow for improved disease surveillance in high TB burden countries.
Moreover, additional facilities in which molecular diagnosis of TB and drug susceptibility
testing can be performed are required.
Supplementary Materials: The following supporting information can be downloaded at: https:
//www.mdpi.com/article/10.3390/genes13030475/s1, Figure S1. Sectional map of Nairobi, Kenya;
Figure S2. Phylogenetic tree showing MTBC lineage classification of all analyzed MTBC isolates in
urban and slum settings of Nairobi, Kenya; Figure S3. Phylogenetic tree showing <12 SNP clusters in
urban and slum settings of Nairobi, Kenya; Figure S4. Phylogenetic tree showing <5 SNP clusters in
urban and slum settings of Nairobi, Kenya; Figure S5. Phylogenetic tree showing genotypic drug
resistance in urban and slum settings of Nairobi, Kenya; Table S1. Study Variables.
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